How Does Depression Work?

In 2019, a team of researchers at the University of Cambridge analyzed data from more than 135,000 people with depression and found something that changed how scientists think about the disorder. The traditional view held that depression was fundamentally a problem of low serotonin. The data told a different story. Depression is not one thing. It is at least six distinct subtypes, each with different neural signatures, different underlying biology, and different responses to treatment.

This matters because the conversation people have about depression, both in medical settings and in public, has not caught up with the science. Depression is not a shortage of happiness. It is not a failure of willpower. It is a family of disorders with measurable, testable mechanisms that researchers are only beginning to map.

The short answer

Depression is a brain disorder involving disrupted signaling in neural circuits that regulate mood, motivation, sleep, appetite, and stress response. The leading scientific models point to a combination of neurotransmitter imbalances (particularly serotonin, norepinephrine, and dopamine), chronic inflammation, HPA axis dysfunction, and reduced neuroplasticity. Treatment works by addressing these mechanisms, but which treatment works depends heavily on which specific subtype of depression a person has.

The full picture

When mood regulation breaks down

The brain maintains emotional equilibrium through a network of circuits connecting the prefrontal cortex (responsible for planning and context), the amygdala (which processes emotional threat), and the hippocampus (which forms memories and helps terminate stress responses). In depression, this network becomes dysregulated. The prefrontal cortex loses some of its ability to quiet an overactive amygdala. The hippocampus shrinks slightly, a change visible on MRI scans and linked to chronically elevated cortisol.

This is not a matter of thinking differently. The hardware is actually different. Studies using functional MRI show that people experiencing depression recruit these circuits differently when processing negative emotions. The amygdala fires more intensely and stays active longer. The prefrontal cortex, which would normally provide context and dampen the response, shows reduced activity. It is a circuit running out of calibration.

The chemistry underneath

The oldest and most familiar explanation is the monoamine hypothesis: depression results from low levels of serotonin, norepinephrine, and dopamine. This led to the development of selective serotonin reuptake inhibitors (SSRIs) like Prozac, Zoloft, and Lexapro, which increase the amount of serotonin available between neurons by blocking its reabsorption.

The monoamine hypothesis has genuine explanatory power but is incomplete. If low serotonin caused depression, raising it immediately should relieve symptoms. It does not. Patients typically wait two to six weeks after starting an SSRI before feeling better. This delay suggests that the neurochemical change is only the trigger. What follows is slower: the growth of new neural connections, the remodeling of circuits, and the gradual restoration of emotional regulation capacity.

More recent research has expanded the chemical picture. Dopamine, which drives motivation and reward anticipation, is also depleted in many forms of depression. This explains why depressed individuals often describe feeling emotionally flat, not just sad. They lack the pull of desire itself. Norepinephrine, which regulates alertness and energy, contributes to the fatigue and cognitive fog that often accompany the disorder.

The stress system gone wrong

The hypothalamic-pituitary-adrenal (HPA) axis is the body’s central stress response system. When you encounter a threat, the hypothalamus releases corticotropin-releasing hormone (CRH), which signals the pituitary gland to release ACTH, which tells the adrenal glands to pump out cortisol. Cortisol is useful in short bursts. It mobilizes energy and sharpens attention. When the HPA axis is chronically activated by ongoing stress, grief, trauma, or sleep deprivation, cortisol stays elevated.

Elevated cortisol over months and years is neurotoxic, particularly in the hippocampus. This is one reason why prolonged stress can trigger depression and why people who have experienced trauma are at significantly higher risk. The hippocampus normally provides negative feedback that winds down the stress response. When cortisol damages hippocampal neurons, that feedback loop weakens. The stress system becomes a loop with no off switch.

The inflammation connection

In 2023, a landmark study published in Nature Medicine found that roughly 30% of people with major depression have elevated markers of chronic inflammation in their blood, specifically high levels of a protein called C-reactive protein (CRP). These patients do not respond well to standard antidepressants. They do respond to anti-inflammatory treatments, including some SSRIs that also have anti-inflammatory properties.

The mechanism runs through the immune system. Chronic peripheral inflammation sends signals across the blood-brain barrier that activate microglia, the brain’s immune cells. Activated microglia release inflammatory cytokines that disrupt neurotransmitter synthesis and impair neuroplasticity. In other words, an immune problem in the body becomes a mood problem in the brain. This finding explains why depression is so common among people with autoimmune disorders, chronic infections, and metabolic conditions.

How the gut talks to the brain

The gut microbiome produces roughly 95% of the body’s serotonin, mostly in the enterochromaffin cells of the intestinal lining. This serotonin does not cross the blood-brain barrier, but it influences the gut-brain axis through the vagus nerve, a major highway of communication between the gut and the brain. Changes in gut microbiome composition have been linked to depression in both animal and human studies.

A 2019 randomized controlled trial published in Nature Microbiology found that consuming a fermented diet (yogurt, kefir, kimchi, and similar foods) reduced depressive symptoms in people with major depression, independent of any change in antidepressant medication. The proposed mechanism: these foods shift the composition of gut bacteria in ways that reduce intestinal inflammation, which in turn reduces the inflammatory signal traveling to the brain.

Why it matters

Depression is the leading cause of disability worldwide, according to the World Health Organization. More than 280 million people live with it globally. Yet the average delay between symptom onset and receiving appropriate treatment is around 11 years. Part of that delay is stigma. Part of it is systemic. But a significant part is that the prevailing cultural narrative about depression as a chemical imbalance that antidepressants fix oversimplifies a disorder that is far more heterogeneous and far more treatable than most people realize.

The subtypes matter enormously for treatment outcomes. Patients with high-inflammation depression respond to anti-inflammatory approaches. Patients with atypical depression, characterized by preserved mood reactivity but severe fatigue and oversleeping, respond preferentially to MAOIs. Patients whose depression is dominated by anxiety symptoms tend to need higher doses or combined treatments. A person who has tried one antidepressant and found it ineffective has not tried and failed at depression treatment. They have tried one treatment for one subtype.

Understanding the mechanisms also changes how we think about prevention. Sleep disruption, chronic inflammation, and HPA axis dysregulation are all modifiable risk factors. Addressing them before they reach clinical threshold is not a luxury. It is the most scalable intervention available.

Common misconceptions

“Depression is just a chemical imbalance and you fix it with pills.”

The chemical imbalance theory is not wrong, but it is radically incomplete. Depression involves structural changes in the brain (reduced hippocampal volume, altered prefrontal cortex activity), immune system activation, stress axis dysfunction, and gut microbiome disruption. Medication addresses the neurotransmitter component in many patients, but it does not fix a shrunken hippocampus or quiet overactive microglia. Most good treatment plans combine medication with sleep optimization, exercise (which promotes neuroplasticity), and sometimes dietary changes.

“If someone wanted to be happy, they could just choose to be.”

Depression is not low mood. It is a disorder of motivation, cognition, and physiological regulation. Brain imaging studies show that people with depression have reduced capacity in the reward circuitry that drives motivated behavior. Asking a depressed person to choose happiness is like asking a person with diabetes to choose to have normal blood sugar. The underlying mechanism is broken. Choices follow from functional biology, not the other way around.

“Depression comes from bad life circumstances, not biology.”

Both are true and neither is sufficient alone. Life circumstances matter, and adverse experiences (trauma, loss, chronic stress) are powerful triggers. But they work through biological mechanisms: an overactive stress axis, chronic inflammation, and changes in neural circuitry. The biology does not make the suffering less real. It makes it more tractable. When you understand that depression has a physical basis, you gain access to physical interventions that work.

Key terms

Monoamine neurotransmitters: A class of neurotransmitters including serotonin, dopamine, and norepinephrine that regulate mood, motivation, alertness, and reward. Most antidepressants work by increasing their availability in the brain.

HPA axis: The hypothalamic-pituitary-adrenal axis. The brain’s central stress response system. Dysregulation of the HPA axis, with chronically elevated cortisol, is one of the most replicated biological findings in depression research.

Neuroplasticity: The brain’s ability to form new neural connections and remodel existing circuits. Most effective depression treatments (medication, therapy, exercise) work by promoting neuroplasticity, not by directly correcting chemical imbalances.

Microglia: The brain’s resident immune cells. When chronically activated by peripheral inflammation, they release inflammatory molecules that disrupt neurotransmitter function and impair the neural remodeling that underlies recovery.

Vagus nerve: The tenth cranial nerve, running from the brainstem to the abdomen. It is the primary communication highway of the gut-brain axis and a route through which gut inflammation can influence brain function and mood.

C-reactive protein (CRP): A marker of systemic inflammation measured in blood. Elevated CRP (above 3 mg/L) is found in roughly 30% of people with major depression and predicts poor response to standard antidepressants.